PLEASANTON, Calif., May 16, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today released the latest Veeva 2023 Trends in HCP Omnichannel Engagement Report. Findings show synchronizing digital marketing with biopharma field engagement with healthcare professionals (HCPs) increases marketing effectiveness by 23%. The report uncovers there is a large opportunity to improve impact as only 27% of HCPs engaged with the field also see digital advertising within a three-month timeframe.
Aggregated media measurement and health data from Veeva Crossix and field activity from Veeva CRM, the report reveals:
"In light of new trends in patient and HCP behavior, marketing and field teams need to align and drive omnichannel experiences," said Sarah Caldwell, general manager of Veeva Crossix Analytics. "Companies that strategically synchronize marketing initiatives with field activity will drive more relevant HCP conversations and increase the impact of their brand promotions."
The report analyzes new Veeva Crossix advertising and CRM data from January to December 2022. Veeva Crossix measures marketing effectiveness across direct-to-consumer (DTC) and HCP marketing for more than 230 life sciences brands in the U.S., including 14 of the top 15 global biopharma companies. CRM software tracks more than 80% of all field force calls in the U.S.
Additional Information
To read the full Veeva 2023 Trends in HCP Omnichannel Engagement Report visit: veeva.com/trendsHCPomnichannelreport Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As aPublic Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-K for the fiscal year ended January 31, 2023, which you can find here (a summary of risks which may impact our business can be found on pages 9 and 10), and in our subsequent SEC filings, which you can access at sec.gov.
Contact:
Alison Borris
Veeva Systems
925-226-8821
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$224.15 |
Daily Change: | 4.48 2.04 |
Daily Volume: | 1,465,186 |
Market Cap: | US$36.390B |
December 05, 2024 November 24, 2024 November 20, 2024 November 19, 2024 October 24, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB